We are live on ! Find out more

Xencor

XNCR

Market cap $1.98B

26.61 USD

-0.01

0.04%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

26.28

-0.33

1.24%

1 day

-0.04%

5 days

2.35%

1 month

33.58%

3 months

121.57%

6 months

108.87%

Year to date

78.35%

1 year

217.92%

5 years

-21.18%

10 years

28.92%

About: Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

Employees: 260

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 37.5%

Neutral 62.5%

Negative 0%

Xencor to Present at the 2026 Cantor Global Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor's website located at w.

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Zacks Investment Research

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.41 per share a year ago.

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

Xencor Reports Second Quarter 2026 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. “We are excited to present XmAb819 results at ESMO this fall and for other fast-approaching key milestones across our wholly owned clinical pipeline,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “E.

Xencor Reports Second Quarter 2026 Financial Results

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company (“Alexion”), to resolve a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz) (the “Settlement Agreement”).Under the Settlement Agreement, Xencor will receive $10.

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

Zacks Investment Research

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data

Xencor remains a Strong Buy, driven by pipeline progress in oncology and inflammatory disorders. XmAb819 demonstrated a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients; pivotal study initiation is targeted for 2027. XmAb942, a next-gen anti-TL1A for ulcerative colitis, is differentiated by extended dosing and superior TL1A inhibition; interim phase 2b data are expected by the end of 2026.

Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the European Society of Medical Oncology (ESMO) Congress 2026, to be held October 23-.

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor: Bullish On Their Increasingly In-House Pipeline

Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR's oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR's valuation in the near term.

Xencor: Bullish On Their Increasingly In-House Pipeline

Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Zacks Investment Research

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™